| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Direct oral anticoagulants vs LMWH for cancer-associated thrombosis - updated evidence on bleeding risk, recurrence and patient-reported outcomes: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Duaa Asad, Ahris Abid, Muhammad Bari Hassan, Munesh Kumar Nenwani, Sunil Dev, Sanjeet Kumar, Fnu Sapna, Payal Bai, Sadia Siddique, Inshal Jawed, Farah Alam, Farah Abdul Razzaq, Favour C Mekowulu, Shafaq Jabeen and Agha MW Mirza |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Inshal Jawed, Chief Physician, Senior Researcher, Department of Medicine, Dow University of Health Sciences, Baba-e-urdu Karachi, Karachi 75350, Sindh, Pakistan. inshaljwd@gmail.com |
| Key Words |
Cancer-associated thrombosis; Direct oral anticoagulants; Low molecular weight heparin; Venous thromboembolism; Bleeding risk |
| Core Tip |
Patients with cancer, direct oral anticoagulants (DOACs) are effective, as are low-molecular-weight heparin, in preventing new blood clots. DOACs raise the risk of bleeding, mainly in the digestive tract and urinary organs. Patients choose DOACs since they improve their quality of life and are convenient. Doctors have to consider the cancer type, possibility of bleeding and platelet levels before deciding on the treatment. Taking into account what the patient wants and what the medical team considers best is necessary. Anticoagulation treatment can be improved in multidisciplinary thrombosis programs, emphasizing the importance of providing ongoing information and support to patients. |
| Publish Date |
2026-04-23 11:05 |
| Citation |
Asad D, Abid A, Hassan MB, Nenwani MK, Dev S, Kumar S, Sapna F, Bai P, Siddique S, Jawed I, Alam F, Razzaq FA, C Mekowulu F, Jabeen S, Mirza AM. Direct oral anticoagulants vs LMWH for cancer-associated thrombosis - updated evidence on bleeding risk, recurrence and patient-reported outcomes: A systematic review. World J Methodol 2026; 16(2): 110380 |
| URL |
https://www.wjgnet.com/2222-0682/full/v16/i2/110380.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v16.i2.110380 |
